rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Ligand Pharmaceuticals Incorporated

LGND · Nasdaq

Health CareBiotechnologyLeading

LGND stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 12.0% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
52 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$65.2M
Officials’ trades on record
12
Institutions holding
386 (+52)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$24.6M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

12 disclosed lines: House 11, Senate 0, executive 1; 5 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k29 May 2026filed 8 Jun 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k15 May 2026filed 1 Jul 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k3 Mar 2026filed 7 Apr 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k15 Jan 2026filed 13 Feb 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k5 Jan 2026filed 13 Feb 2026
Katherine M. Clark House: U.S. House ClerkMA05soldspouse$1k–$15k22 Oct 2020filed 3 Dec 2020
Katherine M. Clark House: U.S. House ClerkMA05soldspouse$1k–$15k22 Oct 2020filed 3 Dec 2020
Katherine M. Clark House: U.S. House ClerkMA05boughtspouse$1k–$15k3 Apr 2020filed 29 May 2020
Lamar Smith House: U.S. House ClerkTX21bought$1k–$15k1 Dec 2017filed 9 Jan 2018
James B. Renacci House: U.S. House ClerkOH16bought$1k–$15k11 Jan 2016filed 27 Jan 2016
James B. Renacci House: U.S. House ClerkOH16bought$1k–$15k24 Aug 2015filed 8 Sep 2015
James B. Renacci House: U.S. House ClerkOH16bought$1k–$15k3 Aug 2015filed 25 Aug 2015

Insiders

Buy orders, 12 months0
Sale orders, 12 months33
Buyers · sellers0 · 9
WhoDidSharesTraded
Andrew ReardonCLO & Secretarysold833at $302.512 Oct 2026filed 6 Oct 2026
Andrew ReardonCLO & Secretarysold1,976at $303.542 Oct 2026filed 6 Oct 2026
Andrew ReardonCLO & Secretarysold1,535at $304.522 Oct 2026filed 6 Oct 2026
Andrew ReardonCLO & Secretarysold404at $306.182 Oct 2026filed 6 Oct 2026
Andrew ReardonCLO & Secretarysold235at $307.192 Oct 2026filed 6 Oct 2026
Andrew ReardonCLO & Secretarysold17at $307.742 Oct 2026filed 6 Oct 2026
Martine ZimmermannDirectorsold1,200at $285.0010 Sep 2026filed 14 Sep 2026
Andrew ReardonCLO & Secretarysold300at $283.993 Sep 2026filed 8 Sep 2026
Andrew ReardonCLO & Secretarysold1,800at $285.173 Sep 2026filed 8 Sep 2026
Andrew ReardonCLO & Secretarysold2,115at $286.363 Sep 2026filed 8 Sep 2026
Andrew ReardonCLO & Secretarysold385at $287.533 Sep 2026filed 8 Sep 2026
Andrew ReardonCLO & Secretarysold400at $288.983 Sep 2026filed 8 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders386+52 on the quarter
New · exited93 · 41
Reported value$7.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20263,100,996$980.2M+139,073+4.7%
Invesco Ltd.added · filed 14 Aug 20261,201,644$379.8M+378,040+45.9%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,138,316$359.8M+38,049+3.5%
Jupiter Topco LLCnew · filed 14 Aug 20261,040,578$328.9M+1,040,578
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026870,950$275.3M+22,861+2.7%
STATE STREET CORPadded · filed 7 Aug 2026826,539$261.3M+47,683+6.1%
FMR LLCadded · filed 13 Aug 2026762,827$241.1M+166,700+28.0%
FRANKLIN RESOURCES INCadded · filed 13 Aug 2026752,044$237.7M+178,867+31.2%
CONGRESS ASSET MANAGEMENT COadded · filed 7 Jul 2026659,911$208.6M+155,274+30.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026589,020$186.2M+30,086+5.4%
31 Mar 2023 – 30 Jun 2026
170274378Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Andrew Reardon Company insiderCLO & Secretary · last 2 Oct 20260 · 15
Martine Zimmermann Company insiderDirector · last 22 Sep 20260 · 1
Jason Haas Company insiderDirector · last 12 Aug 20260 · 2
Octavio Espinoza Company insiderChief Financial Officer · last 12 Aug 20261 · 12
Todd C. Davis Company insiderChief Executive Officer · last 30 Jun 20265 · 8
Stephen L. Sabba Company insiderDirector · last 16 Jun 20263 · 11
Jason Aryeh Company insiderDirector · last 11 Jun 202628 · 30
John L. Lamattina Company insiderDirector · last 10 Jun 20261 · 10
John W. Kozarich Company insiderDirector · last 5 Jun 202611 · 30
Nancy Ryan Gray Company insiderDirector · last 5 Jun 20260 · 2
Gilbert Ray Cisneros, Jr. HouseCA31 · last 29 May 20264 · 0
Donald J. Trump Executive branchWhite House Office · last 15 May 20260 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 202515.3%
Free cash flow marginFY 2025 · to 31 Dec 202518.2%
Return on capital employedFY 2025 · to 31 Dec 20252.7%
Cash conversionFY 2025 · to 31 Dec 202539.7%
Research spendFY 2025 · to 31 Dec 202530.3%
Share count trendFY 2025 · to 24 Feb 20260.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$174.9M
Free cash flowFY 2025 · to 31 Dec 2025$48.9M

Analyst forecasts

No analyst forecasts yet.